Provides cell-engineering research services and tools that help pharmaceutical and biotechnology, agricultural, and industrial customers develop biological products. Also offers governments services to monitor and analyze biological threats.
10-K for FY2025, filed Feb 26, 2026Ginkgo does not make end products; instead, we offer biological R&D services on our platform to enable our customers to bring their…View ↗
Because biosecurity is a matter of national and global security, our primary biosecurity customers are governments. Our biosecurity…View ↗
Canopy, which helps our customers generate high value genomic data from strategically-positioned nodes (like airports and border…View ↗
Our pharmaceutical and biotechnology customers use our services to develop new manufacturing methods for gene therapies, biologics…View ↗
Our customers in agriculture use our services to improve the performance and manufacturability of existing agricultural biologics, develop…View ↗
Our customers in industrial biotech use our services to achieve a variety of objectives, such as improve the manufacturing efficiency and…View ↗
Customers pay for cell-engineering research, data packages and lab automation through fixed or cost-based fees, paid upfront or as work proceeds; some agreements also include milestone payments and royalties on customers’ product sales. Biosecurity customers pay fees for data, analysis and services.
10-K for FY2025, filed Feb 26, 2026We generate Cell Engineering revenue primarily through service and license agreements for our tools and solutions offerings. Under our…View ↗
For agreements where licenses or assignments are considered separate performance obligations or represent the only performance obligation…View ↗
Cell Engineering consists of end-to-end cell engineering solutions and cell engineering tools offerings for biological R&D. The Company’s…View ↗
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by product or service ↗$170.2M
10-K for FY2025, filed Feb 26, 2026
$170.2M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Cell Engineering
Mix
10-K for FY2025, filed Feb 26, 2026 |
78%
FY2022: 30%
|
Cell Engineering, FY2025
$132.7M Sources
|
Mix |
|
Service
|
22%
FY2022: 63%
|
Service, FY2025
$37.4M Sources
|
|
|
Product
|
0.0%
FY2022: 7.4%
|
Product, FY2025
$0 Sources
|
Government agencies engage Ginkgo as a prime contractor or R&D subcontractor; pharmaceutical and biotechnology, agriculture, and industrial customers use its cell-engineering services and tools.
10-K for FY2025, filed Feb 26, 2026Ginkgo is a trusted partner to government agencies worldwide as they work to protect people, supply chains, and critical resources, all by…View ↗
Our pharmaceutical and biotechnology customers use our services to develop new manufacturing methods for gene therapies, biologics…View ↗
Our customers in agriculture use our services to improve the performance and manufacturability of existing agricultural biologics, develop…View ↗
Our customers in industrial biotech use our services to achieve a variety of objectives, such as improve the manufacturing efficiency and…View ↗
10-K for FY2025, filed Feb 26, 2026
For the year ended December 31, 2025, one customer in the Cell Engineering segment accounted for 15% of the Company’s total revenue, while…View ↗
No. It lost $312.8M in FY2025.
10-Q for Q3 FY2026, filed Nov 9, 2026
−$41MView ↗
8-K, filed Apr 7, 2026
On April 3, 2026, Ginkgo Bioworks, Inc. (the “Seller”), a wholly owned subsidiary Ginkgo Bioworks Holdings, Inc. (the “Company”) completed…View ↗
Shrinking. Revenue fell 46% in 4 years, from $313.8M in FY2021 to $170.2M in FY2025, about 14% a year.
Customer-facing tools
The older report describes an end-to-end cell-programming service platform; the latest report adds offerings that let customers run some research in-house and buy lab automation and data-generation services.
10-K for FY2022, filed Mar 13, 2023 10-K for FY2025, filed Feb 26, 2026Ginkgo’s platform is a generalized, horizontal platform that provides end-to-end cell programming services to our customers, enabling them…View ↗
Ginkgo does not make end products; instead, we offer biological R&D services on our platform to enable our customers to bring their…View ↗
Reconfigurable Automation Cart (“RAC”) SystemsView ↗
To this end, we have introduced three new data generation services to provide high-quality data at the scale, price, and speed that…View ↗
Downstream payments
The older report described service fees plus customer value sharing through milestones, royalties or equity. The latest says it is moving toward milestones and commercial royalties instead of equity, and has removed downstream value sharing from some program types.
10-K for FY2022, filed Mar 13, 2023 10-K for FY2025, filed Feb 26, 2026Our cell programming business model mirrors the structure of our platform and we are compensated in two primary ways. First, we charge…View ↗
Second, as the key enabling technology for our customers’ products, we have historically negotiated a value share with our customers (in…View ↗
Biosecurity services
The older report described biosecurity infrastructure in development; the latest names Canopy for biomonitoring and Horizon for digital threat surveillance.
10-K for FY2022, filed Mar 13, 2023 10-K for FY2025, filed Feb 26, 2026We care deeply how our platform is used and recognize biosecurity as a necessary complement to our cell programming work. Biology has the…View ↗
Canopy, which helps our customers generate high value genomic data from strategically-positioned nodes (like airports and border…View ↗
Competes with AbCellera, Codexis, Senti Bio, WuXi Biologics, Evotec, Charles River Laboratories, HighRes Biosolutions, Automata, Thermo Fisher Scientific, Verily, Biobot, BlueDot, Airfinity, Public Health, and BGI
10-K for FY2025, filed Feb 26, 2026Within certain end markets, Ginkgo may compete against vertically-focused biotechnology companies providing cell engineering R&D…View ↗
Loading...